Nile Therapeutics Inc.


in
Nile Therapeutics Inc. announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure. The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key assessments include glomerular filtration rate, tubular function, renal plasma flow, urine output, mean arterial pressure, and various biomarkers. The trial is expected to enroll 27 heart failure patients.